VBIV

VBI-2601 (HBV Immuno-Therapeutic)

Hepatitis B Virus (HBV)

Stage (next event)

Expected Date

Phase 1B/2A

Q4 2020

Catalyst Info & Data Links

TITLE: VBI-2601 for Hepatitis B Virus (HBV)  - Phase 1B/2A (Data)


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 1B/2A (Data)


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?


PRIOR DATA

PRESS RELEASES

Mechanism of Action

MECHANISM OF ACTION / RATIONALE

  • VBI believes VBI-2601 has the unique potential to do this by targeting B- and T-cell immunity through several key mechanisms of action, including neutralizing circulation of the hepatitis B virus, blocking infection of hepatocytes via Pre-S1 immunity, and enabling immune-mediated clearance of HBV-infected hepatocytes (Learn more HERE).

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon